Myotonic dystrophy type I (DMI) is a multisystem disorder with a variable phenotype. The involvement of peripheral nerves in DM I disease is controversial. The DM I animal model DM300 transgenic mice that carry 350 to 500 CTG repeats express a mild DMI phenotype but do not exhibit motor or sensory pathology. Here, we investigated the presence or absence of peripheral neuropathy in transgenic mice (DMSXL) that carry more than I ,300 CTG repeats and display a severe form of DMI. Electrophysiologic, histologic, and morphometric methods were used to investigate the structure and function of peripheral nerves. We observed lower compound muscle action potentials recorded from hind limb muscles and slowing of sciatic nerve conduction velocity in DMSXL versus control mice. Morphometric analyses showed an axonopathy and neuronopathy in the DMSXL mice characterized by a decrease in numbers of myelinated motor axons in sciatic nerve .and in spinal cord motor neurons. Pathologic alterations in the stmcture of hind limb neuromuscular junctions were also detected in the DMSXL mice. These results suggest that peripheral neuropathy can be linked to a large CTG expansion and a severe fonn of DM I.
INTRODUCTION
Myotonic dystrophy type I (DMI) is a multisystemic autosomal dominant disorder with a highly variable clinical phenotype (1, 2). The genetic basis for DM1 is the abnonnal amplification of a cytosine-thymine-guanine (CTG) trinucleotide repeat in the 3' untranslated region of the DM protein kinase (DMPK) gene on chromosome 19q (3, 4) . The number of DNA CTG repeats usually increases in successive generations of DM I families, and the size of triplet correlates with the severity of the disease_ In healthy individuals without DM I, 5 to 35 copies of repeat have been observed. Patients with CTG expansion containing 50 to 80 CTG repeats are almost asymptomatic. Individuals with I 00 to I ,000 CTG repeats develop a disease in adult life (the classic form of OM!) that is characterized by progressive muscle wasting with myotonia. However, the most severe form of OM I is congenital disease; the mutation becomes unstable, and after 3 to 4 generations, the CTG repeat lengthens to up to 2,000 repeats (5) . This fonn of disease is characterized by extreme myotonia and muscular atrophy (6) . Other systemic manifestations such as cataracts, cardiac conduction defects, endocrine dysfunction, respiratory failure, and changes in the CNS with mental retardation and hypersomnia are recognized as common extramuscular manifestations in patients with OM I (2, 7-11). Although a number of clinical reports have drawn attention to the occasional presence of a peripheral neuropathy in patients with OM I (J 2-16), other reports dispute completely the presence of neuropathy in patients (17) (18) (19) (20) (21) . Therefore, additional studies are needed to determine the involvement of the peripheral nervous system (PNS) in OM I .
During the last few years, the use of animal models for studying DMI mechanisms has become more frequent because access to the nervous system is only possible at the end stage of the disease. To investigate the primary involvement of the PNS in DMI, we previously analyzed DM300 transgenic mice carrying 350 to 500 CTG repeats and displaying a mild DM l phenotype and found that those mice do not exhibit sensory or motor neuropathy (1). To explore this issue further, we examined new transgenic mice canying more than 1,300 CTGs and displaying more severe DMI features (22) .
MATERIALS AND METHODS
All anima l procedures were conducted according to local guidelines for care and use of experimental animals, and all analyses and measurements were performed blinded to animal genotype.
Generation of DMSXl Transgenic Mice
Production of transgenic mice carrying the human genomic OM I region with expanded repeats of approximately 350 to 500 CTGs has been reported (23) . The mice are of a mixed background. Heterozygous, homozygous, and wildtype mice are obtained from the same litter. Recently, new transgenic mice carrying more than I ,300 CTG repeats were obtained, resulting from large expansions of the CTG repeat in successive generations. The newly generated mice (called DMSXL) display a severe phenotype: I) they are remarkably small; 2) they exhibit muscles abnormalities such as myotonia and muscle weakness; 3) they display abnormalities in the metabolism of multiple messenger RNAs, notably in brain, heart, and muscle; 4) their skeletal muscle showed abnomml splicing patterns for the insul in receptor and chloride channel I transcripts; 5) and they have a very high mortality rate, approximately 60% of them die before 7 months of age (22) .
Because heterozygous mice ex pressing a low B evel of DMPK transcripts have no obvious phenotype (22) , only homozygous transgenic mice were used. Wild-type mice from the same litter were analyzed because they provide the best controls.
Electrophysiologic Studies
Electrophysiologic investigations were carried out with a Viking TIT EMG machine (Nicolet Biomedical Inc, Madison, WI), using platinum subdermal electrodes (10 mm/30 gauge) for stimulation, recording, and grounding. Sixteen mice (8 DMSXL mice with a body weight of 22.19 ± 2.5 g and 8 wildtype control mice with a body weight of31.75 ± 3.06 g), aged 5 to 6 months, were studied. Each animal was anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and fixed in the prone position. Right and left sciatic nerves were stimulated to record the supramaximal motor responses or compound muscle action potentials (CMAPs) from hind! limb muscles (flexor digitorum brevis, gastrocnemius, and tibialis anterior), as previously described (24) . Compound muscle action potential area and amplitude were measured using the negative peak and onset latency methods. To measure nerve conduction velocity (NCV) of the sciatic nerve, the stimulating electrodes were placed proximally near the sciatic nerve at the level of the limb girdle and distally at the level of the ankle with the recording electrodes placed just over the flexor digitorum brevis.
Animal Perfusion and Tissue Preparation
After electrophysiologic studies, the mice were deeply anesthetized and then transcardially perfused with 0.1-moi/L phosphate-buffered saline (PBS) containing 0. 1% heparin and 0. 1% procaine, followed by a solution of 4% parafOtmaldehyde in 0.1-moVL PBS at pH 7.4. Sciatic nerves, lumbar spinal cord, and hind limb muscles (gastrocnemius and tibialis anterioris) were removed from each animal. To prepare cryostat sections, tissues were first cryoprotected in 30% sucrose overnight, frozen in liquid N 2 , and stored at -80°C. For semithin section preparat ion, the tissues were placed in 2% Os0 4 in PBS for 3 hours, followed by dehydration in a series of graded ethanols and embedded in Epon (I, 25).
Sciatic Nerve Section Analysis
For histologic and morphometric analysis, 1-~J..m-th ick semithin transverse sections were cut from the common trunk of sciatic nerves and stained with toluidine blll!e. Neurolucida Software and Stereolnvestigator program (both from MBF Bioscience, Williston, VT) were used to measure the area of nerve cross sections and the diameter of myelinated axons and to count the total number of myelinated axons on I 0 nerve sections from 5 DMSXL an.d 5 wild-type control mice as described (1, 25) .
To count only myelinated motor fibers, cryostat sciatic nerve sections (12 ~J-rn) were prepared and double immuno- 
Analysis and Quantification of Motor Neurons in the Spinal Cord lumbar Enlargement
The physical disector method was used to estimate the number of motor neurons in 2-mm segments of [umbar spinal cord (26) . Adjacent cryostat transverse sections, 20 IJ-m thick, were prepared from lumbar spinal cord segments taken from 5 wild-type and 5 DMSXL mice. Approximately 50 sampling sections, called disector pairs, were prepared from each animal, and every third disector pair was used to count the number of motor neurons. The sections were irnmunostained with anti-ChAT and were photographed; the images of each disector pair were carefully aligned using Adobe Photoshop and then imported into the lmageJ 1.40 program. Only ChATpositive neurons in the top section (tops) of the disector pair were marked and counted. The number of the tops was multiplied by 2 to estimate the number of neurons in the disector pair. Because we used every third disector pair, the number of neurons of each studied disector pair was multiplied by 3. Then the estimated number of neurons of 17 d isector pairs was combined to obtain the total number of motor neurons present in the 2-nun segment of lumbar spinal cord. All analyses and counts were performed blinded to the animal type. The results were exported to Microsoft Excel (Microsoft Corp, Redmond, WA) for statistical analysis.
To investigate whether the surviving motor neurons of DMSXL mice express pathologic tau protein, cryostat spinal cord sections from control and DMSXL mice were incubated either with monoclonal antibody PHF-1 (developed by Dr Peter Davies, Albert Einstein College of Medicine, NY; dilution I :500), which specifically recognizes the phosphorylated serines 396 and 404 at the C-terminus of tau protein, or with A T8 monoclonal antibody (Thermo Fisher Scientific, Waltham, MA; dilution I: 1000), which recognizes the phosphorylated serines 199 and 202. Other sections were incubated with tau-! monoclonal antibody, which recognizes normal tau protein (produced by Dr Beat Riederer, University of Lausanne, Switzerland; dilution I: I 0).
Analysis of Neuromuscula r Junctions on Hind Limb Muscle Sections
Serial cryostat longitudin al 20-~J..m-thick sections were prepared from hind limb muscles. First, the sections were incubated for 45 minutes in I j..Lg/mL tetramethyl rhodamineconjugated a -bungarotoxin (a-BTX; Invitrogen, Life Technologies) and then incubated ovemight with the primary polyclonal antibody anti-NF 200 kd (1:500; ABI982, Millipore), followed by incubation with the secondary antibody conjugated To avoid counting and measuring the same junction twice, every third section was used. To determine whether the EPs are innervated, we followed the nerve fibers on several sections to determine whether if they made contact w ith the EP. The percentage of denervated EPs was estimated, and the morphometric parameters (area, shape complexity, and fluorescence intensity of rhodamine-a-BTX labeling) of every EP were measured and calculated as previously described in detai I (I , 24, 25). More than I ,400 EPs were measured rrom each mouse line (n = 6 mice). All analyses and counts were perfonned blinded to the animal genotype.
Statistical Analysis
Results of DMSXL transgenic mice analysis were compared w ith the values of wild-type control mice. The distribution of values was checked for normality, and transfonnations were applied when necessary. Then !-way analysis of variance was performed followed by the Holm-Bonferroni post hoc test. The distribution of diameters was compared using a i test. In all perfonned tests, p < 0.05 was considered significant.
RESULTS

Electrophysiologic Evidence of Peripheral Nerve Abnormality in DMSXL Mice
Compound muscle action potentials and NCVs were recorded after sciatic nerve stimulation of both right and Every DMSXL mouse examined exhibited a decrease in both CMAP parameters and NCY. In DMSXL mice, the amplitude of CMAPs recorded from gastrocnemius muscles was greatly reduced (42%) ·compared with controls (Fig. I) . There was a similar significant fall in CMAP (38.86%) in tibialis anterior muscles. Moreover, a slowing (14%) of sciatic NCV was observed in DMSXL compared w ith control m[ce (Fig. l) . Although the decrease in NCV is slight, it is significant (p < 0.0 I). To rule out the possibility that the reduction in CMAP and NCV in DMSXL mice was due to the small size and weight of these transgenic m ice, we measured the CMAP and the NCY in control mice that had a similar size and weight range to the DMSXL. The results demonstrated that the reduction in CMAP and NCY in DMSXL mice was independent of the size and the weight of the mouse. The reduction in CMAP and NCY in DMSXL indicates muscle and nerve dysfunction. 
Axonopathy and Muscle Dystrophy Underlie the Electrophysiologk Abnorm()lity in DMSXL Mice
A lthough the general cytoarchitecture of sciatic nerves did not differ noticeably between DMSXL and control mice, the mean area of nerve section in DMSXL mice was smaller than in control mice (0.113 ± 0.0 II vs 0.156 ± 0.016 mm 2 , p < 0.01) (Figs. 2A-E) . Moreover, the diameter of myelinated fibers in DMSXL sciatic nerves was smaller, and the thickness of myelin sheath was reduced (19%). The size-frequency histogram based on the measurement of approx imately I ,500 fibers from each mouse line showed that the peak axon diameter in DMSXL mice was significantly shifted to a smaller diameter versus that in w ild-type mice (p < 0.00 I) (Fig. 2F) . In addition, the number of all myelinated fibers in sciatic nerves in DMSXL mice was reduced by 6%. Nevertheless, counts of ChAT-positive axons on sciatic nerve sections double immunolabeled for ChAT and NF revealed a loss of approximately 19% of myelinated motor axons in DMSXL mice (Fig. 3) . Because myelinated motor axons represent only 22% of the total number of myelinated axons, the loss of 6% of the total number of myelinated fibers corresponds to a preferential loss of motor axons. Together with the morphometric results, these observations indicate the presence of an axonopathy in DMSXL sciatic nerves w ith a specific loss of large myelinated fibers. These results were independent of the size and weight of the mice.
Evidence of Motor Neuronop()t hy in the lumbar Spinal Cord of DMSXL Mice
To verify whether the loss of motor axons observed in DMSXL mice resulted from only a degeneration of myelinated motor axons ("dying baclk neuropathy") or rather from neuronopathy that affects neuron cell bodies, we used the physical disector method to estimate the number of motor neurons in lumbar enlargement of spinal cord (! Fig. 4 ). There was a 24% reduction in the number of motor neurons in DMSXL mice versus controls (I ,348 ± 49 vs I ,758 ± 79, p < 0.01). These results indicate that the lumbar motor neurons in DMSXL mice are affected by a neuronopathy.
Because tau abnormalities are found in brain neurons of DM patients, we perfonned immunohistochemical staining for pathologic and normal tau proteins. Incubation of spinal cord sections with PHF-1 or AT8 antibodies demonstrated that, in DMSXL mice, most surviving motor neurons displayed a strong immunostaining (Figs. 58, D) , whereas in control wild-type mice, all motor neurons were PHF-1 and AT8 negative (Figs. SA, C) . In contrast, the normal tau protein was highly expressed in control motor neurons compared with DMSXL motor neurons (Figs. SE, F) . A link between overexpression of a kinase in DM brain neurons and the presence of abnormal tau protein has been reported (27) .
Pathologic Changes in the Structure of Neuromuscular junction.s in DMSXL Mice
Histologic examination .of gastrocnemius muscle sections labeled with rhodamine-a-BTX and NF antibody showed that control mice displayed EPs w ith a typical pretzel 1 (A, B), AT8 (C, D) , or tau-1 (E, F) antibodies. Pathologic hyperphosphorylated tau proteins are highly expressed in motor neurons in DMSXL mice as demonstrated by strong PHF-1 (B) or AT8 (D) staining. Wild-type mice motor neurons do not show visible PHF-1 (A) or AT8 (C) staining. Normal tau protein is intensely expressed in wild-type motor neurons (E) and is faintly expressed in DMSXL motor neurons (F). Data are representative of 5 mice/group. shape and strong fluorescent labeling, with 98% of them in direct contact with the nerve terminal (Figs. 6A-C) . In DMSXL mice, however, numerous EPs exhibited lengthened shapes and faint labeling, and only 77% had axonal terminal contact (Figs. 6D-F) . Morphometric analysis showed a significant decrease in the size (16.4%) and shape complexity ( 17.5%) ofEPs in DMSXL mice (Figs. 6G, H) . Moreover, the concentration of acetylcholine receptors on postsynaptic membranes assessed by measuring the a -BTX fluorescence labeling intensity was reduced by 23% (Fig. 6T) .
DISCUSSION
Involvement of the CNS and other organs in patients with DM I is well known, but PNS involvement in DM I remains controversial. Clinically, the diagnosis of peripheral neuropathy in patients with DM l is mainly detected by electrophysiologic tests and supported by neurologic examination. Several reports have described a reduction in CMAP, a slowing of maximal and minimal motor NCV, or an increase in the minimal latency of F waves in DM patients, suggesting the presence of pathologic changes in peripheral nerves patients with DM I ( 18, 20, 21 ) . It is important to emphasize that studies confirming or denying association of peripheral neuropathy with DM I disease involved patients of unknown genotype because the molecular basis of DM 1 was not yet identified when those reports appeared. Consequently, the earlier studies did not take into consideration the relationship between the expansion of the CTG repeat and the severity of the clinical features. Therefore, we believe that the conflicting results are probably due to different lengths ofCTG repeats in the patients.
We previously studied transgenic mice (DM300) canying 350 to 500 CTG repeats and displaying mild DM I features (23, 42) , and analysis of the sciatic nerve, lumbar dorsal root ganglia, and spinal cord of those mice revealed neither axonopathy nor neuronopathy (I). Moreover, no signi:ficant changes can be detected either in CMAP index or in NCV in DM300 transgenic mice (43) . These results suggest that the length of CTG repeats (350-500) probably was not sufficient to induce peripheral neuropathy in that mouse model (I). Because CMAP amplitude represents the total number of stimulated axons and NCV provides information about the rate at which a neural impulse propagates along myelinated fibers (44) , the reduction in CMAP amplitude and NCV detected in DMSXL mice indicates nerve dysfunction. This correlates with clinical studies that found peripheral nerve dysfunction in patients with DMI (12-16, 29, 32, 33) . Structural pathologic changes that probably caused the dysfunction of peripheral nerves in the mice were detected in sciatic nerves, lumbar motor neurons, and neuromuscular j unctions. ln particular, the s ize-frequency distribution of myelinated fiber diameters indicates that the 6% reduction in the total number of myelinated fibers in DMSXL mice was essentially a loss of large axons, which correspond to motor fibers in sciatic nerve (45) . The reduction of 19% of ChATpositive axons confirmed a preferential loss of motor axons, and the decrease in the number of motor neuron cell bodies indicates the presence of a motor neuronopathy. Moreover, the higher expression of hyperphoshorylated tau protein in DMSXL mice motor neurons argues for increased kinase activity (27) . It is worth noting that comparable motor neuronopathy and pathologic changes in neuromuscular junctions have been described in patients with DM I (46). Indeed, Wheeler et al. (46) demonstrated the presence of ribonuclear foci in motor neurons spinal cord autopsy and the high expression of CUGexp RNA and sequestration of MBNLI protein in postsynaptic nuclei of neuromuscular junctions in muscle biopsies. Other studies have emphasized that dramatic changes in talll isoform expression in brain neurons is associated with the presence of large CTG expansion in the brains of patients with DM1 (27, (47) (48) (49) ; the expanded! CUG repeats may affect RNA metabolism of several genes and act as a gain-of-function mutation (48) .
We believe that the motor neuropathy detected in DMSXL mice is independent of possible alterations in the thyroid or pancreatic [3-cell ftmction because the DM300 transgenic mice used to generate DMSXL mice did not develop either motor or sensory neuropathy (I). Moreover, the neuropathy detected in DMSXL transgenic mice showed a loss in the number of motor neurons, whereas neuropathies induced by hypothyroudism or diabetes are mainly characterized by a deficiency in myelination and progressive distal loss of axonal terminals but without perikaryal loss (50, 51) . Our data are consistent with other studies demonstrating a selective loss of functioning motor units and alterations of neuromuscular excitability in patients with OM I (52-55).
Genotype-phenotype correlation studies anso report that muscular disability and the severity of hand muscle myotonia depend on the CTG repeat length in leukocyte DNA (56) (57) (58) (59) (60) (61) . The severity of cardiac conduction abnormalities and arrhythmia in DMl is also directly related to age and CTG repeat length (62) . Moreover, an association between the CTG repeat size and cognitive impairment has been described (63, 64) . Because transgenic mice carrying 350 to 500 CTG repeat did not have peripheral neuropathy ( 1), whereas DMSXL mice undoubtedly have motor neuropathy, we conclude that there is a correlation between the development of neuropathy in DM I transgenic mice and the size of the CTG triplet. However, it should be noted that the relationship between the length of the CTG repeat and the severity of DM 1 features does not always hold true, and there are some exceptions. Indeed, some authors claim that cataract, gastrointestinal, respiratory insufficiency sleep disorder, and other OM features are not correlated with the length of the CTG triplet (56, 58) . Because in DM !-affected individuals the instability of the triplet repeats induces somatic heterogeneity characterized by a variable size in different tissues, some investigators hypothesize that the somatic mosaicism might be one possible explanation for the lack of precise correlation between the number of CTG repeats in leukocyte DNA and the severity of DM I in its multisystemic aspect.
In conclusion, analyses of DMSXL transgenic mice carrying a large CTG expansion and expressing a severe DMI phenotype provide evidence that these mice have a motor neuropathy that we infer to be linked to their large CTG expansion. In the future, we will investigate whether sensory neuropathy can also be linked to the long CTG repeat and severe fonn of DM I.
